Medicines from US and Alvotech Sign Licensing and Commercialization Agreement to Push Two Biosimilars in the US and Asian Markets

Investors typically watch as Mehsui, a Taiwanese pharmaceutical company, has entered into a strategic licensing and commercialization agreement with Alvotech, an American firm operating in the biosimilar sector. This collaboration aims to advance the launch of two biologic similar drugs in both the United States and key Asian markets.